Agrace, the biggest nonprofit hospice organization in Wisconsin, has been chosen to take over the hospice program that was previously run by Crossing Rivers Health. The two groups have signed a Preferred Partner Agreement to make sure people in the Prairie du Chien area still have access to high-quality end-of-life care. This new partnership comes after Agrace worked with Oakwood Village Communities and shows the organization’s continued growth throughout the state.
Health Technology Insights: NJ Taps Garden State Venture Partners for MedTech Growth
Crossing Rivers Health decided to stop running its hospice program so they can focus more on their main healthcare services. As part of this change, patients who are currently getting hospice care from Crossing Rivers Health will have the chance to switch to Agrace’s care by the end of September. This ensures that patients and their families who rely on compassionate end-of-life care won’t experience any interruption in the services they receive.
“Agrace is honored to work with such a respected partner and is happy to be named their Preferred Hospice Partner,” said Lynne Sexten, Agrace’s President and CEO. “This Preferred Partner agreement is another step in Agrace’s efforts to improve access to high-quality, people-first, nonprofit hospice care across the upper Midwest.”
Health Technology Insights: Bio Usawa, DEK Partner to Boost Biotech Access in West Africa
Agrace has been serving communities in southern Wisconsin since 1978, offering hospice care to people of all ages in the comfort of their homes or other preferred settings. Their approach focuses on giving physical, emotional, and spiritual support during the final stages of life, with a strong emphasis on dignity and compassion.
With this partnership, patients in the Crossing Rivers Health service area can expect a smooth transition and ongoing access to trusted hospice services. Agrace’s expansion into this community is another step in their mission to make sure everyone who needs end-of-life care gets thoughtful and reliable support, no matter where they live in Wisconsin.
Health Technology Insights: Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Schizophrenia
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source- PR Newswire
